July 2020 Clinical Watch Newsletter

August 4, 2020

In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing’s disease. Lastly, we review claims data to identify the trends for use of Dupixent®.
For more information about a topic, please contact Janelle Sheen, Karen Powell or Mary-Beth Plum. Be sure to watch for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.

Previous Flipbook
August 2020 Clinical Watch Newsletter
August 2020 Clinical Watch Newsletter

Next Article
Five elements to consider when implementing an Electronic Visit Verification (EVV) Program
Five elements to consider when implementing an Electronic Visit Verification (EVV) Program

Conduent can help states to swiftly and seamlessly implement their Electronic Visit Verification EVV Progr...

Explore our Clinical Watch Newsletter

Learn More